
X4 Pharmaceuticals, Inc.
XFOR
|
NASDAQ
|
1 Sledující
Company Quality
Profitability Score
50/100
Solvency Score
33/100
Dividends
Dividends data currently unavailable.Earnings
8/14/2025
in 55 days
-
Revenue est.
-4.17
EPS est.
My Notes
You haven't added any notes for this stock yet. Use this space to record your insights or strategies.
Profile
Healthcare
Sektor
Biotechnology
Průmysl
Dr. Paula Ragan Ph.D.
CEO
143
Zaměstnanci
Boston
Centrála
US
Země
Key Metrics TTM
Valuation
Market cap.
$16MEnterprise Value
-$22MPrice to Earnings
39.50Price to Sales
0.52Price to Book
25.13Price to Cash Flow
-0.14Profitability
Return on Assets
11.23%Return on Equity
29.32%Return on Invested Capital
-8.04%Gross Margin
82.42%Operating Margin
-27.28%Net Margin
46.54%Liquidity
Quick Ratio
3.58Current Ratio
3.70Cash Ratio
1.56Inventory Turnover
1.78Asset Turnover
0.24Total Liabilities
$107MSolvency
Debt to Assets
0.02Debt to Equity
N/AInterest Coverage
-1.24Equity Ratio
0.18Long-term Debt to Cap.
0.05Altman Z-Score
-1.60Performance
Earnings Waterfall
Debt level and coverage
Earnings
Feed
There are no posts to show right now.